Clinical Trial Update: Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of TRM-1, a TRAIL-R1 monoclonal antibody, in relapsed or refractory Non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• TRM-1 (TRAIL-R1 monoclonal antibody)

Snippet

Sponsor: Human Genome Sciences Inc. | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED